Study Design
Our study was a retrospective case-control review that included patients admitted to the hospital over a 10-month period. All study subjects developed diarrhea and were subsequently tested for the presence of C. difficile toxin A in the stool, as determined by an enhanced optical immunoassay. The study took place in a 420-bed tertiary hospital [...]
ABSTRACT
Purpose: We analyzed the relationship between the use of proton pump inhibitors (PPIs) and the development of Clostridium difficile-associated diarrhea (CDAD) in hospitalized patients .
Methods: We conducted a retrospective case-control study in a 420-bed tertiary hospital serving a rural population in a 10-county region. We identified all patients in the hospital who had been tested [...]
A study by Kramer and associates also evaluated the efficacy of paliperidone ER in a multiphase trial. In an eight-week run-in phase, 530 patients were hospitalized and received open-label paliperi-done. Dosing was flexible, starting at 9 mg once daily, and the dose could be adjusted between 3 and 15 mg once daily. The most commonly [...]
INDICATIONS
Paliperidone was approved in December 2006 for the acute treatment of schizophrenia and for the long-term maintenance treatment of schizophrenia in April 2007.
INTRODUCTION
Schizophrenia is a chronic mental illness that affects between 0.5% and 1% of the population in the U.S. today. Even though schizophrenic patients characteristically have psychoses, including hallucinations and delusions, this debilitating disease impairs their functional capacity to learn, work, care for themselves, maintain interpersonal relationships, and sustain general living skills. Forty percent to 60% [...]
Crohn’s Disease with Fistula
Adalimumab (Humira, Abbott), a fully human monoclonal antibody that targets tumor necrosis factor (TNF), has been found efficacious for inducing and maintaining remission in patients with Crohn’s disease (CD). According to data presented at the meeting, adalimumab offers sustained responses for the 20% to 30% of patients whose course is complicated by [...]
When early reports of increased mortality rates caused the premature discontinuation of the European Organisation for Research and Treatment of Cancer trial (EORTC 18961) of a post-surgical vaccine for patients with node-negative malignant melanoma, it cast a pall over the vaccine horizon, noted Dr. Eggermont. At a Pfizer-sponsored satellite symposium on cytotoxic T-lymphocyte antigen-4 (CTLA-4) [...]
© 2008 HIV/AIDS News & Information